Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.36M | 18.88M | 18.80M | 17.95M | 15.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.36M | 18.88M | 18.80M | 17.95M | 15.54M |
| Cost of Revenue | 8.24M | 10.68M | 10.33M | 9.83M | 8.50M |
| Gross Profit | 6.12M | 8.20M | 8.47M | 8.12M | 7.04M |
| SG&A Expenses | 2.80M | 2.33M | 2.02M | 2.29M | 1.76M |
| Depreciation & Amortization | 432.50K | 420.30K | 425.70K | 380.90K | 343.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.27M | 15.40M | 14.94M | 14.22M | 12.01M |
| Operating Income | 1.10M | 3.48M | 3.86M | 3.73M | 3.53M |
| Income Before Tax | -10.65M | -9.52M | 847.80K | 1.99M | -94.30K |
| Income Tax Expenses | 239.20K | 1.52M | 232.00K | -1.33M | -800.60K |
| Earnings from Continuing Operations | -10.89M | -11.04M | 615.80K | 3.33M | 706.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.89M | -11.04M | 615.80K | 3.33M | 706.40K |
| EBIT | 1.10M | 3.48M | 3.86M | 3.73M | 3.53M |
| EBITDA | 1.53M | 3.91M | 4.29M | 4.06M | 3.88M |
| EPS Basic | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.07B | 1.07B | 1.07B | 1.02B | 1.01B |
| Average Diluted Shares Outstanding | 1.07B | 1.07B | 1.08B | 1.03B | 1.02B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |